NL-OMON24198已完成不适用
A 6-month, multicenter, non-interventional Study to evaluate the Effectiveness and Quality of life impact of the Insulin glargine/Lixisenatide fixed ratio combination in patients with type 2 diabetes mellitus uncontrolled with basal insulin + metformin ± SU: an observational study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 107
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational non invasive
入排标准
入选标准
- •* T2DM patients on basal insulin for at least 3 months + metformin ± sulfonylureas;
- •* For which the Investigator has decided to prescribe IGlarLixi independently from entry in the study (within 1 week of study entry);
- •* BMI = 30 kg/m2
- •* = 18 years of age
排除标准
- •* Diagnosis for T1DM;
- •* Use of mealtime insulin or premix insulin within 6 months before switching to IGlarlixi;
- •* Current use of GLP-1 RA;
- •* Hypersensitivity to IGlarLixi or any of its components;
- •* Pregnant (or intention to become pregnant during the course of the registry) or breast-feeding woman;
- •* Incapability to fill in PRO questionnaires (at the discretion of the investigator)
研究者
相似试验
未知
Unknown
on-drug study to assess the suitability of assessment scales in Japanese individuals with Down syndrome aged 6-30Down SyndromeJPRN-jRCT1080222828Chugai Pharmaceutical Co., Ltd.40
进行中（未招募）
不适用
A retrospective, 12-month, multicenter study to evaluate real-world brolucizumab effectiveness and safety in Japanese patients with neovascular age-related macular degeneration (nAMD)JPRN-jRCT1050210159Takuma Okada500
已完成
4 期
R3 Acetabular Hip system in patients with degenerative joint disease.Degenerative joint disease.Musculoskeletal - Other muscular and skeletal disordersACTRN12608000234314Smith & Nephew70
进行中（未招募）
Unknown
A study investigating the effectiveness, safety and quality of life in participants with age related visual impairment (macular degeneration) who have switched to faricimab, under real world conditions in Germanyeovascular age related macular degeneration (nAMD)Eye DiseasesISRCTN27514808Roche Pharma (Roche Germany)620
已完成
不适用
Multicentre Non-interventional Study of Treatment Outcome in Heart Failure Patients with Hyperkalaemia under RAASi-treatment Receiving Veltassa in Routine PracticeE87.5HyperkalaemiaDRKS00014825Vifor Pharma Deutschland GmbH22